Abstract
Exposure to seasonal allergens may contribute to spatiotemporal variations in asthma exacerbations. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab, reduced the annualized asthma exacerbation rate (AAER) versus placebo in patients with severe, uncontrolled asthma, across all seasons. This post hoc analysis evaluated the effect of tezepelumab on seasonal asthma exacerbations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
